Literature DB >> 2570732

Use of microbleeding and an ultrathin endoscope to assess gastric mucosal protection by famotidine.

T K Daneshmend1, P J Prichard, N K Bhaskar, P J Millns, C J Hawkey.   

Abstract

We have developed an ultrathin endoscope for repeated endoscopy in unsedated subjects and used it with assessment of bleeding rates to investigate aspirin-induced gastric mucosal injury and its prevention by famotidine. Compared with placebo, 900 mg of aspirin b.i.d. taken for 48 h caused significant endoscopic injury (median grade 3.5, interquartile range 2-4, modified Lanza scale, p less than 0.01), with an increase in mucosal bleeding from 2.0 (geometric mean; 95% confidence limits, 1.1-3.9) microliters/12 min, to 8.3 (2.4-28.8) microliters/12 min (p less than 0.05). Famotidine (20 mg b.i.d.) raised intragastric pH and reduced endoscopic antral injury (median 1.5, interquartile range 0.5-2, p less than 0.05) and bleeding [3.1 (1.2-8.3) microliters/12 min, p less than 0.01] to levels not significantly different from placebo [1 (0-1) and 2.0 (1.1-3.9) microliters/12 min, respectively]. By contrast, 2 mg of famotidine b.i.d. had no significant effect on intragastric pH endoscopic injury or bleeding rates. The two assessments of gastric mucosal injury correlated strongly (r = 0.71, p less than 0.01). The reduction in bleeding with famotidine tended to be higher, the greater the intragastric pH (r = 0.66, p = 0.057). Ultrathin endoscopy is a simple technique that validates gastric mucosal bleeding as a measure of acute gastric mucosal injury in humans. Acid suppression is an effective method of ameliorating this injury.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570732     DOI: 10.1016/0016-5085(89)91502-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  5 in total

1.  Placebo-controlled comparison of piroxicam-beta-cyclodextrin, piroxicam, and indomethacin on gastric potential difference and mucosal injury in humans.

Authors:  L Santucci; S Fiorucci; S Chiucchiù; A Sicilia; L Bufalino; A Morelli
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

2.  Abolition by omeprazole of aspirin induced gastric mucosal injury in man.

Authors:  T K Daneshmend; A G Stein; N K Bhaskar; C J Hawkey
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

3.  Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration.

Authors:  M A Hull; A Knifton; B Filipowicz; J L Brough; G Vautier; C J Hawkey
Journal:  Gut       Date:  1997-02       Impact factor: 23.059

Review 4.  [Mucosa protective therapy with long-term nonsteroidal antirheumatic drugs].

Authors:  Wolfgang Cozzarini; Johannes Rath; Andreas Bauer; Ina Györög; Manfred Györög; Markus Prenner; Theodorus Trianto; Hermann Maderbacher; Erik Höller; Bernhard Grusch; Christian Sebesta
Journal:  Wien Med Wochenschr       Date:  2003

Review 5.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.